Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.
Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. OT-58, their lead drug development candidate, has been optimized as an enzyme replacement therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.
Manchester Pharmaceuticals is a specialty pharmaceutical company focused on the identification, development, FDA approval and commercialization of new therapeutic modalities to address the special needs of patients with ultra-rare diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.